Among these pathways, the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is particularly critical, as its dysregulation is frequently linked to tumor progression, resistance to therapy, and poor outcomes across multiple cancer types (2–4). Here, MTOR is linked to neoplasm.